Valmet’s Advantage ViscoNip press technology to enhance performance and product quality at five Lee & Man tissue machines in China

Valmet has been selected to replace five shoe presses with its Advantage ViscoNip press technology on Lee & Man tissue machines (TM 3, 9, 10, 11 and 12) at mills in Chongqing, Jiangxi and Guangdong, with all upgrades expected operational in 2026. The order—partly recorded in Valmet's Q2 2025 orders received and mostly in Q4 2025—has an undisclosed value and emphasizes improved pressing performance, energy savings and maintenance benefits; Lee & Man operates over 10 bases and produces ~9 million tonnes annually (including 1.3 million tonnes of tissue). The deal reinforces Valmet's installed base (100+ ViscoNip presses globally) and supports Lee & Man's product quality and efficiency near-term, though financial impact on either company is unspecified.

Analysis

Market structure: Direct winners are Valmet (VALMT.HE) as technology vendor and Lee & Man (2314.HK) as early adopter; aftermarket service providers and OEMs with spare-parts/service businesses also gain (potentially +1–3% incremental service revenue per installed press over 2 years). Losers are legacy shoe-press suppliers and commodity tissue producers who cannot match moisture uniformity and energy efficiency; that increases pricing pressure on low-end tissue by enabling product differentiation and small unit-cost advantages (~1–4% per tonne).

Competitive dynamics: The order deepens Valmet’s installed base (100+ ViscoNip units globally) and raises switching costs via maintenance/service contracts, likely increasing Valmet’s margin mix over 12–36 months. Competitors (e.g., ANDR.VI, VOW3.DE) face a higher bar for R&D/price concessions; expect a 6–18 month competitive window where Valmet can capture disproportionate share of Chinese rebuilds.

Cross-asset and timing impacts: Immediate market moves should be muted (days) but expect visible order-intake and guidance revisions in Valmet’s Q4 2025 release and incremental topline in 2026 as five machines commission. Credit spreads for mid-tier tissue producers could tighten 10–50bp if productivity gains translate to cashflow; commodity pulp/energy demand impact is marginal and unlikely to move commodity prices materially.

Risks & catalysts: Tail risks include installation failures or warranty exposure leading to a reputational hit (share downside 15–30%), China capex slowdown, or a cheap domestic alternative undercutting Valmet. Catalysts that would accelerate upside: additional multi‑machine Chinese contracts within 3–9 months, Lee & Man margin upgrades in FY2026 guidance, or services contract announcements that convert one-off hardware sales into recurring revenue.

Key Decisions for Investors

• Establish a 2–3% long position in Valmet (VALMT.HE) size of portfolio, horizon 6–12 months; target +20% upside on re‑rating if order momentum in China continues, set stop-loss at -12% to limit execution/warranty risk.
• Establish a 1–2% long position in Lee & Man (2314.HK) with a 6–12 month horizon; catalyst is improved tissue mix and lower OPEX per tonne — trim or take profits on a 15% price move, stop-loss -10%.
• Initiate a 1:1 pair trade (equal notional) long VALMT.HE vs short ANDR.VI for 6–9 months to express technology-share gain in tissue rebuilds; tighten if competitor announces a counteroffer or ANDR reports share gains.
• Use options to define risk: buy a 12‑month VALMT call spread (buy 25% OTM call, sell 50% OTM call) sized at 0.5–1% portfolio notional to capture upside from additional order announcements while capping premium paid; exit on confirmed acceleration of Chinese orders or at expiry.
• Reduce cyclical pulp/commodity paper exposure by 1–2% (e.g., UPM.HE/SCA.ST) and rotate into industrial automation/providers of aftermarket services for paper machines — re-evaluate after Valmet’s Q4 2025 order-intake release and Lee & Man FY2026 guidance.